论文部分内容阅读
为了探究表皮生长因子受体(epidermal growth factor receptor,EGFR)基因的突变对非小细胞肺癌(non-small cell lung cancer,NSCLC)脑转移患者生存期的影响,我们以2012年1月至2014年12月期间我院收治的123例非小细胞肺癌脑转移患者为回顾性研究对象,按治疗方案的差异分为放射治疗组(36例),化疗组(52例),放射治疗+化疗组(24例)、放化疗+靶向治疗组(13例),观察EGFR基因突变对不同治疗方案的非小细胞肺癌脑转移患者无进展生存期(progression-free-survival,PSF)和总生存期(overall survival,OS)的影响。我们发现,EGFR突变对非小细胞肺癌脑转移患者生存期具有显著影响,EGFR突变型患者生存期明显长于EGFR野生型患者,而基于EGFR突变的靶向治疗患者生存期明显长于辅助治疗患者,因此基于EGFR突变的靶向治疗可有效提升患者生存期。我们的研究为非小细胞肺癌脑转移患者的临床治疗提供了一定的理论依据。
To investigate the effect of epidermal growth factor receptor (EGFR) gene mutation on the survival of non-small cell lung cancer (NSCLC) patients with brain metastases, 123 cases of non-small cell lung cancer patients with brain metastases in our hospital from December to December were retrospectively studied. According to the difference of treatment plan, the patients were divided into radiotherapy group (36 cases), chemotherapy group (52 cases), radiotherapy + chemotherapy group 24 patients) and radiotherapy and chemotherapy + targeted therapy group (13 patients). The progression-free survival (PSF) and overall survival (EGFR) of patients with brain metastases of non-small cell lung cancer overall survival, OS). We found that EGFR mutation has a significant effect on the survival of non-small cell lung cancer patients with brain metastases, EGFR mutant patients had significantly longer survival than EGFR wild-type patients, and EGFR mutation-based targeted therapy patients survival was significantly longer than adjuvant therapy patients Targeted therapies based on EGFR mutations can effectively improve patient survival. Our research provides a theoretical basis for the clinical treatment of patients with brain metastasis of non-small cell lung cancer.